CHANGE IN RATINGS
added to Goldman's Americas Conviction Buy List based on newfound status as sole dominant retailer in consumer electronics. Expect high sales capture from Circuit City and note that competitive dynamics will ease over the short-term. Price target at $33.
upgraded at Credit Suisse to Neutral from Underperform based on solid Q4 results, superior balance sheet and valuation.
upgraded at Citigroup from Sell to Buy. $30 price target. Stock is already pricing in a worse Medicare impact.
downgraded at Merrill Lynch/Bank of America to Neutral. Valuation call, as the stock is up 29% year-to-date. Estimates also cut, to reflect lower Boeing revenue. $14.50 price target.
downgraded at Morgan Stanley to Equal-weight. Management is having trouble cutting costs fast enough.
STOCK COMMENTS / EPS CHANGES
estimates cut at RBC through 2010. Company guided to lower results next quarters, as demand continues to decline. Sector Perform rating and $9 price target.
Coventry Health Care
target raised at Credit Suisse to $19 from $14. Says encouraged by pledge to refine focus and patient investors will be rewarded. Maintained Outperform rating.
estimates cut at UBS through 2010. Company spending more to gain new customers and ARPU is down. Buy rating and $32 price target.
price target raised at Goldman to $24 from $22. Q4 results showed better-than-expected subscriber additions. Also note 4%-6% increase in basic rates. Maintained Neutral rating.
numbers raised at UBS through 2010. Company benefiting from lower capacity in air and ocean shipping. Neutral rating and new $32 price target.
estimates lowered at Barclays through 2010. The entire industry is seeing lower industry shipping volume. Equal-weight rating and $90 price target.
numbers cut at UBS to $68. Estimates also lowered, to reflect lower volumes and higher merger costs. Neutral rating.
numbers lowered at Morgan Stanley through 2011. Company will be hurt by poor trailing one-year performance of mutual funds. Underweight rating and new $8 price target.
estimates cut at UBS through 2011. Revenue is coming down, because of lower professional solutions demand. Sell rating and $6.75 price target.
price target trimmed at Goldman to $46 from $50 after fourth-quarter earnings came in lighter than expectations. See more modest volume growth in U.K. and Canada and note that hedges will limit the flow-through of lower commodity prices in 2009. Maintained Buy rating.
target lowered at Morgan Stanley to $20 a share. Company likely to see higher upfront order cancellations, and weak pricing in the scatter market. Overweight rating.
numbers lowered at UBS to $43. Estimates also cut, to match the company's new guidance for weaker volume. Sell rating.
This article was written by a staff member of TheStreet.com.